Synapse - Carol Portlock

Search Within

Carol Portlock

Results (204)

A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas

Meeting Abstract

Gerecitano, J. F.; Portlock, C.; Hamlin, P.; Moskowitz, C.; Noy, A.; Straus, D. J.; Zelenetz, A. D.; Schulman, P.; Dumitrescu, O.; O'Connor, O. A.
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

Cardiac toxicity

Book Section

Yahalom, J.; Portlock, C. S.
In DeVita, V. T.; Lawrence, T. S.; Rosenberg, S. A. (Eds.) DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 8th ed (2008)

Fulltext@MSK | Save

Results of sequential chemotherapy followed by high dose therapy and autologous stem cell rescue for mantle cell lymphoma: Role of rituximab and functional imaging

Meeting Abstract

Zelenetz, A. D.; Persky, D.; Rice, R. D.; Maragulia, J.; Weaver, S. A.; Portlock, C. S.; Moskowitz, C. H.
Annals of Oncology (2008)

Fulltext@MSK | Save

Sequential chemotherapy followed by high dose therapy and autologous stem cell rescue for mantle cell lymphoma: Impact of MIB-1 on outcome

Meeting Abstract

Zelenetz, A. D.; Moskowitz, C.; Maragulia, J.; Portlock, C. S.; Teruya-Feldstein, J.
Blood (2008)

Fulltext@MSK | Save

Pralatrexate (PDX) produces a high and durable complete response rate in patients with chemotherapy resistant T-cell lymphomas

Meeting Abstract

O'Connor, O. A.; Hamlin, P.; Moskowitz, C.; Portlock, C.; Sarasohn, D.; Dumitrescu, O.; Neylon, E.; Patterson, M.; Zelenetz, A.; Saunders, M.; more...
Annals of Oncology (2008)

Fulltext@MSK | Save

Normalization of FDG-PET pre-ASCT with additional non-cross resistant chemotherapy improves EFS in patients with relapsed and primary refractory Hodgkin lymphoma - Memorial Sloan Kettering protocol 04-047

Meeting Abstract

Moskowitz, C. H.; Nimer, S. D.; Zelenetz, A. D.; Hamlin, P. A.; Horwitz, S. M.; Noy, A.; Portlock, C. S.; Straus, D. J.; Gerecitano, J.; Kewalramani, T.; more...
Blood (2008)

Fulltext@MSK | Save

Sequential RCHOP and yttrium-90 ibritumomab tiuxetan (RIT) is a highly effective regimen for high risk elderly patients with untreated DLBCL

Meeting Abstract

Hamlin, P. A.; Moskowitz, C. H.; Wegner, B.; Noy, A.; Gerecitano, J.; Palomba, M. L.; Portlock, C.; Straus, D.; Pro, B.; Fayad, L.; more...
Annals of Oncology (2008)

Fulltext@MSK | Save

Bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P): Two dosing schedules of a novel phase I regimen in patients with relapsed/refractory indolent and mantle cell lymphomas

Meeting Abstract

Gerecitano, J.; Portlock, C.; Hamlin, P.; Moskowitz, C.; Noy, A.; Straus, D.; Zelenetz, A. D.; Schulman, P.; Dumitrescu, O.; O'Connor, O. A.
Annals of Oncology (2008)

Fulltext@MSK | Save

Long-term cardiac and pulmonary complications of cancer therapy

Journal Article

Yahalom, J.; Portlock, C. S.
Hematology/Oncology Clinics of North America (2008)

Fulltext@MSK | Save

Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): Developing a lymphoma prevention strategy

Journal Article

Portlock, C. S.; Hamlin, P.; Noy, A.; Chey, W.; Gaydos, C. A.; Palomba, L.; Schwartz, I.; Corcoran, S.; Rosenzweig, L.; Walker, D.; more...
Annals of Oncology (2008)

Fulltext@MSK | Save